Talaris Therapeutics attracts $115m Series B
Talaris Therapeutics Inc, a biotechnology company, has raised $115 million in Series B funding.
Talaris Therapeutics Inc, a biotechnology company, has raised $115 million in Series B funding.
Copyright PEI Media
Not for publication, email or dissemination